| Literature DB >> 31824746 |
Gregory Purcell1, Jane McCartney2, Shirley-Anne Boschmans3.
Abstract
BACKGROUND: Antipsychotic agents are associated with harmful adverse reactions which impact negatively on patient adherence and clinical management. Accurate and complete documentation of signs and symptoms in the clinical notes is an important means of communication between healthcare providers, and an essential component in the management of antipsychotic-induced adverse drug reactions. AIM: To determine the impact of an educational intervention on the incidence and extent of antipsychotic-induced adverse drug reaction documentation in patient medical records.Entities:
Keywords: adverse drug reactions; antipsychotics; clinical audit; documentation; educational intervention
Year: 2019 PMID: 31824746 PMCID: PMC6890559 DOI: 10.4102/sajpsychiatry.v25i0.1378
Source DB: PubMed Journal: S Afr J Psychiatr ISSN: 1608-9685 Impact factor: 1.550
FIGURE 1Research design illustrating the pre-intervention, intervention and post-intervention phases.
FIGURE 2Pre-intervention usage trends of antipsychotic drugs.
FIGURE 3Post-intervention usage trends of antipsychotic drugs.
Prevalence of documentation of adverse drug reaction in patient medical notes pre- and post-intervention.
| Presence of documentation | Pre-intervention ( | Post-intervention ( |
|---|---|---|
| No ADR documentation | 36 | 20 |
| ADR documentation | 66 | 82 |
ADR, adverse drug reaction.
, Pre- versus post-intervention: Pearson’s Chi-square p < 0.05;
, No evidence of documentation found;
, Evidence of documentation mentioning signs or symptoms suggestive of an antipsychotic-induced ADR.
Frequency of type of adverse drug reaction documentation in patient medical records with evidence of adverse drug reaction documentation.
| Type of documentation | Pre-intervention % ( | Post-intervention % ( |
|---|---|---|
| Documentation noted ‘Absence of ADR’ | 37.63% | 27.35% |
| (70 instances) | (96 instances) | |
| Documentation noted ‘Presence of ADR’ | 62.37% | 72.65% |
| (116 instances) | (255 instances) |
ADR, adverse drug reaction.
, ADR absence versus ADR presence: Pre-intervention compared to post-intervention: Pearson’s Chi-square p < 0.05;
, Absence of ADR: Evidence of documentation noting the absence of any suspected antipsychotic-induced ADRs;
, Presence of ADR: Evidence of documentation noting the presence of suspected antipsychotic-induced ADRs.
Documentation of suspected antipsychotic-related adverse drug reactions, including multiple instances of the same adverse drug reaction in individual patients.
| ADR documented | Pre-intervention % ( | Post-intervention % ( |
|---|---|---|
| Reversible EPSE | 66.38 | 65.49 |
| Sedation | 14.66 | 12.55 |
| Irreversible EPSE | 4.31 | 5.49 |
| Headache | 2.59 | - |
| Oedema | 2.59 | - |
| General side effect noted | 1.72 | 0.39 |
| Weakness | 1.72 | - |
| Hypersalivation | 0.86 | 6.67 |
| Orthostatic hypotension | 0.86 | 2.34 |
| Loss of libido | 0.86 | - |
| Metabolic side effects | 0.86 | - |
| Diarrhoea | 0.86 | - |
| Fever | 0.86 | - |
| Insomnia | 0.86 | - |
| Cardiotoxicity | - | 0.39 |
| Constipation | - | 0.39 |
| Oculogyric crisis (EPSE) | - | 0.78 |
| EPSE improved | - | 1.96 |
| Urinary retention | - | 0.39 |
| Hypoglycaemia | - | 0.39 |
| Tachycardia | - | 1.57 |
| Nausea/vomiting | - | 0.39 |
| Galactorrhoea | - | 0.78 |
ADR, adverse drug reaction; EPSE, extrapyramidal side effects.
Documentation of adverse drug reactions where one instance represents one patient experiencing that particular adverse drug reaction (i.e. with duplication removed).
| ADR documented | Pre-intervention % | Post-intervention % |
|---|---|---|
| ( | ( | |
| Reversible EPSE | 56.06 | 48.57 |
| Sedation | 15.15 | 18.10 |
| Irreversible EPSE | 6.06 | 2.86 |
| Headache | 4.55 | - |
| General side effect noted | 3.03 | 0.95 |
| Oedema | 3.03 | - |
| Hypersalivation | 1.52 | 12.38 |
| Orthostatic hypotension | 1.52 | 3.81 |
| Metabolic side effects | 1.52 | - |
| Loss of libido | 1.52 | - |
| Weakness | 1.52 | - |
| Fever | 1.52 | - |
| Insomnia | 1.52 | - |
| Diarrhoea | 1.52 | - |
| Cardiotoxicity | - | 0.95 |
| Constipation | - | 0.95 |
| Oculogyric crisis (EPSE) | - | 0.95 |
| EPSE improved | - | 4.76 |
| Urinary retention | - | 0.95 |
| Hypoglycaemia | - | 0.95 |
| Tachycardia | - | 1.90 |
| Nausea/vomiting | - | 0.95 |
| Galactorrhoea | - | 0.95 |
ADR, adverse drug reaction; EPSE, extrapyramidal side effects.